S. Harrison

发表

Cell-penetrating peptides in drug development: enabling intracellular targets.

L. Chen, S. Harrison, 2007, Biochemical Society transactions.

Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats.

Kirk W. Johnson, E. Henriksen, S. Harrison, 2003, American journal of physiology. Endocrinology and metabolism.

Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.

Sean P. Brown, Kirk W. Johnson, Z. Ni, 2017, Journal of medicinal chemistry.

Glycogen synthase kinase 3β inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia

G. Steinberg, S. Kelly, Heng Zhao, 2004, Experimental Neurology.

Casein kinase I « in the Wnt pathway : Regulation of b-catenin function

L. Williams, C. Sakanaka, S. Harrison, 1999 .

Systematic Repurposing Screening in Xenograft Models Identifies Approved Drugs with Novel Anti-Cancer Activity

J. Roix, S. Saha, S. Harrison, 2014, PloS one.

Therapeutic applications of cell-penetrating peptides.

D. Maclean, Randolph M. Johnson, S. Harrison, 2011, Methods in molecular biology.

Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia.

G. Steinberg, S. Kelly, Heng Zhao, 2004, Experimental neurology.

Non-ATP-competitive kinase inhibitors – enhancing selectivity through new inhibition strategies

K. Das, D. Maclean, D. Mendel, 2008, Expert opinion on drug discovery.

Chapter 20. Beyond kinases: Purine-binding enzymes as cancer targets

S. Harrison, Zhenhai Gao, D. Duhl, 2003 .

Chapter 12. Intracellular signaling targets for cancer chemosensitization

T. Gesner, S. Harrison, 2002 .

Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function.

L. Williams, C. Sakanaka, S. Harrison, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Kirk W. Johnson, Sylvia Ma, J. Nuss, 2003, Diabetes.

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia

M. Cope, S. D. Harrison, J. Buysse, 2016, Journal of cardiovascular pharmacology and therapeutics.

Non-ATP-competitive kinase inhibitors – enhancing selectivity through new inhibition strategies

K. Das, D. Maclean, D. Mendel, 2008, Expert opinion on drug discovery.